Amgen: Riding The MariTide Of Monthly Weight Loss
MariTide’s opportunity in diabetes should not be ignored. In addition to reducing weight by 17%, it reduced HbA1c up to 2.2% ...
CNBC on MSN12d
Amgen starts two critical late-stage trials for weight loss drug MariTide
MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and ...
Fierce Biotech12d
Amgen enters Maritime, launching 2 late-stage obesity trials for MariTide
Amgen’s most advanced obesity asset MariTide is entering Maritime—that is, a phase 3 program that includes two freshly ...
BioSpace17h
GLP-1 Players Seek to Differentiate in Increasingly Crowded Weight Loss Space
As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...
STAT11d
Amgen starts late-stage studies of MariTide
Elsewhere in the obesity space — Amgen has initiated Phase 3 trials of its obesity drug MariTide, one in overweight and obese ...
BioPharma Dive11d
Amgen readies pivotal MariTide trials; Novo offers discounted Wegovy
Phase 3 studies for Amgen’s closely watched obesity drug were posted on a federal database. Elsewhere, the FDA cleared for ...
NBC 10 Philadelphia12d
Amgen starts two critical late-stage trials for weight loss drug MariTide
Amgen on Wednesday said it has started two critical late-stage trials for its experimental weight loss injection MariTide, another step in its bid to enter the booming obesity drug market. " ...
Barchart on MSN4d
Is Amgen Stock a Buy, Sell, or Hold as Weight-Loss Drug Trials Kick Off?
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
NBC Washington12d
Amgen starts two critical late-stage trials for weight loss drug MariTide
Amgen said it has started two critical late-stage trials for its experimental weight loss injection, MariTide, another step in its bid to enter the booming obesity drug market. MariTide is a ...